|Values are valid only on day of printing.|
Transfusion and pregnancy are the primary means of sensitization to red cell antigens.
In a given population, 2% to 4% of the general population possess irregular red cell alloantibodies. Such antibodies may cause hemolytic disease of the newborn or hemolysis of transfused donor red blood cells.
Autoantibodies react against the patient's own red cells as well as the majority of cells tested. Autoantibodies can be clinically benign or can hemolyze the patient's own red blood cells, such as in cold agglutinin disease or autoimmune hemoyltic anemia.
Detection of allo- or autoantibodies directed against red blood cell antigens in the settings of pretransfusion testing
Evaluation of transfusion reactions
Evaluation of hemolytic anemia
A positive result (antibody detected) necessitates antibody identification to establish the specificity and clinical significance of the antibody detected.
Negative–no antibody detected.
Clinical evaluation of antibodies identified is necessary to determine their potential for harm to the patient at this time and to assess appropriate action to be taken in the future.
If positive, antibody identification will be performed.
Technical Manual. 14th edition. Edited by RH Walker. Bethesda, MD, American Association of Blood Banks, 2002, pp 379-418